이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Multimodal Ultrasound for Lymphoma Classification and Treatment Response Prediction

2026년 11월 14일 업데이트: Yu Jie, Chinese PLA General Hospital

Multimodal Ultrasound-Based Intelligent Classification and Treatment Response Prediction in the Dynamic Evolution of Lymphoma

This prospective, multicenter, observational cohort study aims to evaluate whether multimodal ultrasound can support the noninvasive classification of lymphoma and the early prediction of treatment response.

Adults with newly diagnosed and previously untreated lymphoma will undergo standardized multimodal ultrasound examinations before treatment, after the first treatment cycle, after the fourth treatment cycle, and during follow-up. Ultrasound examinations will include B-mode ultrasound, color Doppler flow imaging, contrast-enhanced ultrasound, super-resolution contrast-enhanced ultrasound, and ultrasound viscoelasticity imaging. Clinical, laboratory, pathological, molecular, treatment, and follow-up information will also be collected.

The study will investigate differences in ultrasound characteristics among lymphoma subtypes, evaluate changes in ultrasound features during treatment, and develop and validate prediction models integrating imaging and clinical information. The main hypothesis is that multimodal ultrasound features and their early treatment-related changes reflect the biological heterogeneity of lymphoma and can improve noninvasive lymphoma classification and early prediction of treatment response.

연구 개요

상세 설명

This is a prospective, multicenter, observational cohort study of adults with newly diagnosed, previously untreated lymphoma. The study plans to prospectively enroll approximately 2,000 participants across participating centers.

Standardized multimodal ultrasound data will be collected at predefined time points, including before treatment, after the first treatment cycle, after the fourth treatment cycle, and during subsequent follow-up. Imaging modalities include B-mode ultrasound (BUS), color Doppler flow imaging (CDFI), contrast-enhanced ultrasound (CEUS), super-resolution contrast-enhanced ultrasound (SR-CEUS), and ultrasound viscoelasticity imaging (UVE). Clinical and laboratory information, treatment information, pathological diagnosis, immunohistochemical findings, molecular and genetic test results, and follow-up information will also be collected.

The study will first characterize multimodal ultrasound phenotypes across lymphoma categories, including Hodgkin lymphoma and non-Hodgkin lymphoma, indolent and aggressive non-Hodgkin lymphoma, and common pathological subtypes. Longitudinal changes in ultrasound features during treatment will then be evaluated to identify imaging characteristics associated with treatment response.

Using the collected multimodal imaging and clinical data, statistical and machine-learning approaches will be used to develop and validate models for lymphoma classification and early treatment-response prediction. Model development will incorporate imaging features from multiple ultrasound modalities together with relevant clinical information. Model performance will be evaluated using measures of discrimination, calibration, and clinical utility, as appropriate.

The overall objective is to determine whether multimodal ultrasound can provide a noninvasive and repeatable approach for characterizing lymphoma heterogeneity and for identifying treatment response at an earlier stage of therapy.

연구 유형

관찰

등록 (추정된)

2000

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100853
        • 모병
        • Chinese PLA General Hospital
        • 연락하다:
        • 수석 연구원:
          • Jie Yu, PhD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Adults with histopathologically confirmed, newly diagnosed, previously untreated lymphoma who present to participating study centers and have at least one lesion suitable for standardized multimodal ultrasound evaluation will be prospectively enrolled.

설명

Inclusion Criteria:

  1. Age 18 years or older.
  2. Histopathologically confirmed lymphoma.
  3. Newly diagnosed and previously untreated, with no prior radiotherapy, chemotherapy, targeted therapy, immunotherapy, or other systemic antitumor treatment before enrollment.
  4. At least one superficial or otherwise accessible lesion that can be clearly evaluated by ultrasound, such as a cervical, axillary, or inguinal lymph node, with an adequate acoustic window allowing stable acquisition of all five ultrasound modalities.
  5. Expected survival of more than 3 months.
  6. No contraindication to the use of ultrasound contrast agents.
  7. Willingness to undergo multimodal ultrasound examinations before, during, and after treatment and provision of written informed consent.

Exclusion Criteria:

  1. Target lesion located too deeply or obscured by gas or bone, preventing acquisition of a stable ultrasound imaging plane.
  2. Known history of hypersensitivity to any component of the ultrasound contrast agent (sulfur hexafluoride microbubbles).
  3. Known right-to-left cardiac shunt, severe pulmonary hypertension with pulmonary artery pressure greater than 90 mmHg, or uncontrolled hypertension.
  4. Acute respiratory distress syndrome or severe respiratory insufficiency.
  5. Unstable angina or acute myocardial infarction within the previous 1 week.
  6. Pregnancy or breastfeeding.
  7. Inability, in the investigator's judgment, to cooperate with the complete examination procedure or complete the required follow-up.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Newly Diagnosed Untreated Lymphoma Cohort

Adults with pathologically confirmed, newly diagnosed, previously untreated lymphoma who undergo longitudinal multimodal ultrasound examinations and clinical follow-up according to the study protocol.

Participants undergo standardized multimodal ultrasound examinations including B-mode ultrasound (BUS), color Doppler flow imaging (CDFI), contrast-enhanced ultrasound (CEUS), super-resolution contrast-enhanced ultrasound (SR-CEUS), and ultrasound viscoelasticity imaging (UVE). Examinations are performed at predefined study time points, including before treatment, after the first treatment cycle, after the fourth treatment cycle, and during follow-up. The imaging findings are collected for lymphoma classification and treatment-response prediction.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Area Under the Receiver Operating Characteristic Curve for Differentiating Hodgkin Lymphoma From Non-Hodgkin Lymphoma
기간: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model for distinguishing Hodgkin lymphoma from non-Hodgkin lymphoma, using histopathological diagnosis as the reference standard.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Area Under the Receiver Operating Characteristic Curve for Differentiating Indolent From Aggressive Non-Hodgkin Lymphoma
기간: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model for distinguishing indolent from aggressive non-Hodgkin lymphoma, using histopathological classification as the reference standard.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Area Under the Receiver Operating Characteristic Curve for Predicting Complete Response After the Fourth Treatment Cycle Using First-Cycle Multimodal Ultrasound
기간: After completion of Cycle 1 and Cycle 4 (each cycle is 21 or 28 days, depending on the regimen; approximately 3-4 weeks and 12-16 weeks after treatment initiation, respectively).

The area under the receiver operating characteristic curve (AUC) will be used to evaluate the ability of the multimodal ultrasound model to predict complete response (CR) after completion of Cycle 4, using ultrasound features obtained after completion of Cycle 1. Complete response will be assessed by PET/CT or CT according to the study protocol. Each treatment cycle is scheduled to last 21 or 28 days, depending on the prescribed first-line regimen. Assessments are linked to completion of the relevant treatment cycle; the estimated calendar times assume no treatment delays.

After completion of Cycle 1 and Cycle 4 (each cycle is 21 or 28 days, depending on the regimen; approximately 3-4 weeks and 12-16 weeks after treatment initiation, respectively).

2차 결과 측정

결과 측정
측정값 설명
기간
Sensitivity of the Multimodal Ultrasound Model for Identifying Hodgkin Lymphoma
기간: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The percentage of participants with histopathologically confirmed Hodgkin lymphoma who are correctly classified as having Hodgkin lymphoma by the multimodal ultrasound model.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Specificity of the Multimodal Ultrasound Model for Identifying Hodgkin Lymphoma
기간: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The percentage of participants with histopathologically confirmed non-Hodgkin lymphoma who are correctly classified as not having Hodgkin lymphoma by the multimodal ultrasound model.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Sensitivity of the Multimodal Ultrasound Model for Identifying Aggressive Non-Hodgkin Lymphoma
기간: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The percentage of participants with histopathologically confirmed aggressive non-Hodgkin lymphoma who are correctly classified as having aggressive non-Hodgkin lymphoma by the multimodal ultrasound model.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Specificity of the Multimodal Ultrasound Model for Identifying Aggressive Non-Hodgkin Lymphoma
기간: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The percentage of participants with histopathologically confirmed indolent non-Hodgkin lymphoma who are correctly classified as not having aggressive non-Hodgkin lymphoma by the multimodal ultrasound model.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Classification Accuracy of the Multimodal Ultrasound Model for Common Lymphoma Subtypes
기간: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The proportion of participants whose lymphoma subtype is correctly classified by the multimodal ultrasound model, using histopathological diagnosis as the reference standard.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Correlation Between Multimodal Ultrasound Parameters and Tumor Cell Density
기간: At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.

The association between quantitative multimodal ultrasound parameters and tumor cell density determined by pathological assessment will be evaluated using correlation analysis.

At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
Correlation Between Multimodal Ultrasound Parameters and Pathological Microvessel Density
기간: At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.

The association between quantitative multimodal ultrasound parameters and microvessel density determined by pathological assessment will be evaluated using correlation analysis.

At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
Concordance Index of the Multimodal Ultrasound Model for Predicting 2-Year Progression-Free Survival
기간: From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed through 24 months after enrollment.

The prognostic performance of the multimodal ultrasound model for predicting 2-year progression-free survival (PFS) will be evaluated using the concordance index (C-index). PFS is defined as the time from the date of initial histopathological diagnosis of lymphoma to the first documented disease progression, relapse, or death from any cause, whichever occurs first.

From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed through 24 months after enrollment.
Concordance Index of the Multimodal Ultrasound Model for Predicting 2-Year Overall Survival
기간: From enrollment to death from any cause, assessed through 24 months after enrollment.

The prognostic performance of the multimodal ultrasound model for predicting 2-year overall survival (OS) will be evaluated using the concordance index (C-index). OS is defined as the time from the date of initial histopathological diagnosis of lymphoma to death from any cause.

From enrollment to death from any cause, assessed through 24 months after enrollment.
Comparison of Area Under the Receiver Operating Characteristic Curves Between the Multimodal Ultrasound Model and Radiologists
기간: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model will be compared with that of radiologists for lymphoma classification, using histopathological diagnosis as the reference standard.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Incidence of Study Ultrasound-Related Adverse Events
기간: From enrollment through 24 months after enrollment. Record ultrasound-related adverse events throughout follow-up; observe participants for 15-20 minutes after each contrast-enhanced ultrasound examination.

The number and proportion of participants experiencing adverse events related to study ultrasound examinations, particularly contrast-enhanced ultrasound, will be recorded. Contrast-agent-related adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Serious adverse reactions will also be documented.

From enrollment through 24 months after enrollment. Record ultrasound-related adverse events throughout follow-up; observe participants for 15-20 minutes after each contrast-enhanced ultrasound examination.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Jie Yu, PhD, Chinese PLA General Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 1월 1일

기본 완료 (추정된)

2029년 12월 1일

연구 완료 (추정된)

2031년 12월 1일

연구 등록 날짜

최초 제출

2026년 11월 4일

QC 기준을 충족하는 최초 제출

2026년 11월 14일

처음 게시됨 (실제)

2026년 11월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 14일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다